Italy holds more recorded longevity and preventive operators than most European markets, and most of them are the same brand repeated across cities. That shape is usually explained commercially, as a franchise that scaled. Two pieces of Italian law explain it better, and neither of them was written about longevity at all.

The first says that no longevity category can exist, because the law types a healthcare structure by how care is delivered rather than what it is for. The second says that the treatments the international longevity category is built on, the advanced cell and gene therapies, may be supplied outside a clinical trial only inside public and research hospitals. Between them, a private Italian clinic is authorized as a diagnostic and specialist practice like any other, and is shut out of the therapy class entirely.

Neither rule is a verdict on longevity medicine. That is the point worth holding on to, and it is the reason this is a finding about structure rather than a complaint about regulation.

Why can Italy not have a longevity clinic category?

Because the categories are about delivery, and longevity is a purpose.

A private clinic in Italy is authorized under article 8-ter of Legislative Decree 502/1992, inserted by Legislative Decree 229/1999. The article recognizes three types of healthcare structure: inpatient care, outpatient specialist care including diagnostics and laboratory work, and residential care.1 Those three types are defined by the mode of delivery. Does the patient stay overnight, attend an appointment, or live there. Nothing in the scheme asks what the care is for.

The consequence is not that Italy considered a longevity category and declined to create one. It is that the scheme has no axis on which such a category could be placed. A longevity clinic in Italy is authorized as an outpatient specialist facility, indistinguishable in law from a radiology practice or a dermatology clinic.1 To create a longevity category, Italy would have to start typing facilities by purpose, which would be a change to the architecture rather than an addition to a list.

The authorization itself runs through three levels of government. The instrument is national. The requirements are set by the region, which verifies the project against regional need. The authorization to operate is issued by the municipality.1 National instrument, regional requirements, local decision. A market description that treats Italy as one regulatory environment is already too coarse to be useful.

What the record shows:

  • Article 8-ter of Legislative Decree 502/1992 recognizes three structure types, defined by delivery mode: inpatient, outpatient specialist including diagnostics and laboratory work, and residential.
  • No longevity or preventive-medicine facility category exists in the national framework as checked in August 2026.
  • The instrument is national, the structural and technological requirements are regional, and the authorization to operate is issued by the municipality.

The most common failure: reading an absence as a refusal. No Italian authority declined to license longevity clinics. The category is missing the way a colour is missing from a scheme that sorts by shape.

What can an Italian private clinic not lawfully supply?

Advanced therapy medicinal products prepared on a non-routine basis outside a clinical trial, which is the class most of the international longevity conversation is about.

A ministerial decree of January 16, 2015, in force from March 24, 2015, implements in Italy the hospital exemption that article 28 of Regulation (EC) No 1394/2007 created at European level. Under the decree, those products may be used only in research and care institutes, university hospital trusts and public hospitals, and only where no valid therapeutic alternative exists or the patient’s life is in danger. The Italian Medicines Agency authorizes both the production and the use.2

Read the eligible settings again, because the list is the finding. Research and care institutes, university hospital trusts, public hospitals. A private clinic is not among them. The European hospital exemption is the route by which a bespoke cell therapy can reach a patient without a marketing authorization, and it exists across the Union. In Italy it exists and is closed to the private sector.

Two conditions narrow it further and are worth stating so the rule is not overstated in the other direction. The exemption is not a general permission even for the eligible hospitals: it applies only where no valid therapeutic alternative exists or the patient’s life is in danger, which is a rescue standard rather than an elective one.2 And the class is specific. This decree governs advanced therapy medicinal products. It does not govern diagnostics, imaging, laboratory panels, nutrition or the rest of what an Italian preventive clinic actually sells, and nothing here says a private Italian clinic is confined in those.

What the record shows:

  • Advanced therapy medicinal products prepared on a non-routine basis outside a clinical trial may be used only in research and care institutes, university hospital trusts and public hospitals, per the ministerial decree of January 16, 2015.
  • Use is further limited to cases where no valid therapeutic alternative exists or the patient’s life is in danger.
  • The Italian Medicines Agency authorizes both the production and the use.
  • A private clinic is not an eligible setting, so Italy’s implementation of the European hospital exemption excludes it.

The most common failure: treating a European rule as uniformly available. The hospital exemption is a European instrument implemented nationally, and the national implementation is where the door opens or closes. Citing Regulation 1394/2007 without reading the member state’s decree describes a permission the operator may not have.

Does Italy’s ageing law change any of this?

It is real, it is primary, and it is about something else.

Italy’s national ageing commitment rests on Law 33 of March 23, 2023, in force from March 31, 2023, and its implementing Legislative Decree 29 of March 15, 2024. Their subject is care, autonomy, social inclusion and the prevention of frailty in older people.3 That is a substantial policy programme. It is not a longevity-medicine instrument, and it creates no clinical category, no facility type and no route to reimbursement.

The distinction matters because these instruments are routinely cited in market commentary as evidence that Italy has taken a policy position on longevity. Read as elderly-care and autonomy law, which is what they are, they say nothing about whether a private preventive clinic may operate, what it may be called, or what it may supply.

The other document frequently cited alongside them is a proposal rather than an act. The Italian healthspan framework reported in 2026 is a peer-reviewed perspective published in the journal Aging by authors at a foundation and a university, and those authors present it as a staged agenda for evaluation rather than as adopted policy. It is not a government document and carries no legal effect.4 The Atlas has covered that paper on its own terms, as a proposal to make healthspan an Italian public-health number, and the reading has not changed since.

What the record shows:

  • Law 33 of March 23, 2023 and Legislative Decree 29 of March 15, 2024 are real primary instruments whose subject is care, autonomy, social inclusion and the prevention of frailty in older people.
  • Neither creates a clinical longevity category, a facility type or a route to reimbursement.
  • No instrument integrates longevity or healthspan medicine into the national health service as checked in August 2026.
  • The 2026 Italian healthspan framework is a peer-reviewed perspective whose authors describe it as a staged agenda, not a government instrument.

The most common failure: promoting a proposal to a policy. A journal perspective and a statute are both citable, and only one of them binds anyone. A record that reports the first as the second has asserted a regulatory fact that does not exist.

What this check did not cover

Three limits, stated because a negative finding is only as good as its coverage.

Italy’s twenty regions and two autonomous provinces were not checked one by one. The structural and technological requirements for authorization are regional, so a region could in principle name a preventive or longevity category of its own, and nothing read here would have found it. The claim that no such category exists is established from the national framework and is medium confidence for that reason.

The decree setting minimum structural and technological requirements was not covered, and it is the instrument that decides what a facility must physically have before a municipality will authorize it.

The rules that apply to wellness centres and to medical advertising were not examined. Both bear directly on how an Italian operator may present itself, and neither is treated here.

What the two rules explain together

A private Italian clinic is licensed by delivery mode, not by purpose, and cannot obtain a category that says what it is for. It is also excluded, as a private setting, from the therapy class that most defines the international longevity category. What is left available to it is diagnostics, imaging, laboratory work and the specialist outpatient care that article 8-ter already recognizes.

That is a coherent explanation of an Italian market that reads as diagnostics and structured programmes repeated across cities rather than as clinical intervention. It is not the only possible explanation, and this piece does not claim it is the cause of any particular operator’s business model. It claims something narrower and more durable: the legal space an Italian private operator can occupy has a shape, that shape was set by instruments written for other reasons, and any account of the Italian market that starts from commercial strategy alone is describing the second thing that happened.

The country page carries these facts with their issuers, instruments, dates and primary links, which is where the record lives. See Italy, and see Europe for the supranational layer above it, including the advanced therapy regulation this decree implements and the treaty article that reserves the organization and delivery of health services to each member state.

The Atlas of the Healthspan Economy is a neutral record of organizations working on healthspan. It does not recommend any provider and does not give legal advice. See the Italy page, the Europe region, SoLongevity Clinic, Humanitas HealthPro, Palazzo Fiuggi and the Longevity & Preventive pillar, and read the methodology.

A note on what this piece does not claim. Nothing here is legal advice, and no operator named or recorded in Italy is alleged to be operating unlawfully or to be supplying anything it may not supply. The advanced therapy finding concerns advanced therapy medicinal products prepared on a non-routine basis outside a clinical trial; it does not concern diagnostics, imaging, laboratory panels, nutrition or specialist outpatient care, and nothing here says a private Italian clinic is restricted in those. The finding that no longevity or preventive-medicine facility category exists is established from the national framework and not from a sweep of Italy’s twenty regions and two autonomous provinces, so a regional category cannot be ruled out. The decree on minimum structural and technological requirements, the rules applying to wellness centres and the medical-advertising rules were not examined. Italy is not described here as having a national longevity or healthspan policy commitment: Law 33/2023 and Legislative Decree 29/2024 are elderly-care and autonomy instruments, and the 2026 Italian healthspan framework is a peer-reviewed proposal whose own authors call it a staged agenda. No causal claim is made about why any Italian operator chose its business model.

Footnotes

  1. Legislative Decree 502 of December 30, 1992, article 8-ter, as inserted by Legislative Decree 229 of 1999. Three structure types recognized: inpatient care, outpatient specialist care including diagnostics and laboratory work, and residential care. Authorization to operate issued by the municipality following the region’s verification of the project against regional need. Consolidated text read on Normattiva. https://www.normattiva.it/uri-res/N2Ls?urn:nir:stato:decreto.legislativo:1992-12-30;502~art8ter ↩ ↩2 ↩3

  2. Ministry of Health, ministerial decree of January 16, 2015, published in the Gazzetta Ufficiale and in force from March 24, 2015, implementing the hospital exemption under article 28 of Regulation (EC) No 1394/2007. Advanced therapy medicinal products prepared on a non-routine basis outside a clinical trial may be used only in research and care institutes, university hospital trusts and public hospitals, and only where no valid therapeutic alternative exists or the patient’s life is in danger. The Agenzia Italiana del Farmaco authorizes both production and use. https://www.gazzettaufficiale.it/eli/id/2015/03/09/15A01704/sg ↩ ↩2

  3. Law 33 of March 23, 2023, in force from March 31, 2023, and its implementing Legislative Decree 29 of March 15, 2024. Subject matter: care, autonomy, social inclusion and the prevention of frailty in older people. Gazzetta Ufficiale text. https://www.gazzettaufficiale.it/eli/id/2023/03/30/23G00041/SG ↩

  4. Perspective published in Aging, volume 18, July 16, 2026, by authors at the AEON Foundation and the University of Bologna, proposing a staged agenda for integrating healthspan strategies into Italy’s national health service. A peer-reviewed proposal, not a government instrument, and presented by its own authors as an agenda for evaluation. https://doi.org/10.18632/aging.206402 ↩